Structured evidence table for Peppermint Bloating Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Peppermint Bloating Randomized Trial | Evidence from recent systematic reviews and meta-analyses consistently indicates that peppermint oil is the most effective botanical agent, particularly for reducing abdominal pain and overall IBS symptom severity. | 2 | Pastras P (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines. |
| Peppermint Bloating Randomized Trial | The aim of this review is to summarize, compare, and critically evaluate all plant extracts studied for the prevention and treatment of IBS, integrating mechanistic pathways, clinical evidence, and current international guideline recommendations to clarify their therapeutic relevance for clinical practice. | 2 | Pastras P (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines. |
| Peppermint Bloating Randomized Trial | Irritable Bowel Syndrome (IBS) affects 4-15% of the global population, and the limited efficacy of existing pharmacologic therapies has driven growing interest in plant-based therapeutic options among both patients and clinicians. | 2 | Pastras P (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines. |
| Peppermint Bloating Randomized Trial | A comprehensive assessment of all plant extracts investigated in IBS is therefore essential, given the limited effectiveness of conventional treatments and the increasing interest in complementary approaches. | 2 | Pastras P (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines. |
| Peppermint Bloating Randomized Trial | 1 2 3 4 5 5 6 7 6 7 Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of identifiable structural abnormalities []. | 3 | Šuran Jelena (2026) | IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions |
| Peppermint Bloating Randomized Trial | Early studies reported SIBO in up to 60–78% of IBS cases based on lactulose breath testing [,,], though later investigations using more rigorous methods found lower prevalences (e.g., 4–20%) [,]. | 3 | Šuran Jelena (2026) | IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions |
| Peppermint Bloating Randomized Trial | Moreover, increasing evidence implicating the gut microbiota in IBS/SIBO has spurred interest in interventions that modulate microbial communities. | 3 | Šuran Jelena (2026) | IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions |
| Peppermint Bloating Randomized Trial | It affects an estimated 5–10% of the global population and is more common in women, imposing a significant burden on quality of life and healthcare resources []. | 3 | Šuran Jelena (2026) | IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions |
Source documents